Abstract
Our expanding experience with imatinib mesylate provides instructive lessons on the power and pitfalls of targeted therapy. The often impressive initial clinical responses seen with imatinib in a variety of malignancies inevitably give way to the emergence of resistant disease. Recent findings reveal several mechanisms of resistance and suggest ways to overcome them.
Publication types
-
Comment
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Alleles
-
Animals
-
Antineoplastic Agents / therapeutic use
-
Benzamides
-
Cell Line, Tumor
-
Drug Resistance, Neoplasm*
-
Enzyme Inhibitors / therapeutic use
-
Fusion Proteins, bcr-abl / genetics
-
Humans
-
Imatinib Mesylate
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
-
Mutation
-
Neoplasms / drug therapy
-
Neoplasms / genetics
-
Neoplasms / pathology
-
Oncogenes / genetics*
-
Piperazines / therapeutic use
-
Pyrimidines / therapeutic use
Substances
-
Antineoplastic Agents
-
Benzamides
-
Enzyme Inhibitors
-
Piperazines
-
Pyrimidines
-
Imatinib Mesylate
-
Fusion Proteins, bcr-abl